BIOA · XBRL financial data
BioAge Labs financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BIOA's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | 0 | 8,995 |
| Research and development | 59,036 | 73,966 |
| General and administrative | 19,158 | 27,809 |
| Total operating expenses | 78,194 | 101,775 |
| Operating income (loss) | (78,194) | (92,780) |
| Interest expense | 2,367 | 697 |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (71,109) | (80,605) |
| Earnings per share, basic USD per share | (6.63) | (2.24) |
| Earnings per share, diluted USD per share | (6.63) | (2.24) |
| Weighted average shares, basic thousands of shares | 10,727 | 35,933 |
| Weighted average shares, diluted thousands of shares | 10,727 | 35,933 |
Balance sheet
CSVFiscal years (BIOA's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 354,349 | 188,888 |
| Marketable securities | 0 | 92,210 |
| Marketable securities, non-current | — | 4,000 |
| Accounts receivable | 0 | 769 |
| Prepaid and other current assets | 2,754 | 4,926 |
| Total current assets | 357,103 | 286,793 |
| Property and equipment, net | 591 | 963 |
| Right-of-use asset | 200 | 2,785 |
| Total assets | 358,234 | 294,889 |
| Accounts payable | 1,996 | 2,674 |
| Current portion of long-term debt | 6,000 | 2,648 |
| Total current liabilities | 27,775 | 20,138 |
| Long-term debt | 2,502 | 0 |
| Lease liability, non-current | 0 | 2,330 |
| Total liabilities | 35,107 | 22,838 |
| Accumulated deficit | (252,811) | (333,416) |
| Total stockholders' equity | 323,127 | 272,051 |
| Total liabilities and equity | 358,234 | 294,889 |
| Common shares outstanding (cover page) thousands of shares | 35,850 | 44,380 |
Cash flows
CSVFiscal years (BIOA's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (71,109) | (80,605) |
| Stock-based compensation | 6,979 | 11,691 |
| Net cash from operating activities | (51,522) | (81,627) |
| Purchases of property and equipment | 366 | 719 |
| Net cash from investing activities | (366) | (95,216) |
| Proceeds from issuing common stock | 0 | 17,155 |
| Net cash from financing activities | 381,199 | 11,469 |
| Net change in cash | 329,392 | (165,461) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| BioAge Labs | 52,666 | 298 | (30,959)* | 46.0M | 11.4 quarters | 10-QSep 30, 2026 |
| Caribou Biosciences | 26,057 | 1,607 | (22,518)* | 108.0M | 3.9 quarters | 10-QSep 30, 2026 |
| Fate Therapeutics | 43,942 | 0 | (27,800) | 121.6M | 5.1 quarters | 10-QSep 30, 2026 |
| Protalix BioTherapeutics | 27,420 | 19,896 | (10,400)* | 80.6M | 2.6 quarters | 10-QJun 30, 2026 |
| Protara Therapeutics | 17,076 | not reported | (15,389)* | 59.1M | 10.5 quarters | 10-QJun 30, 2026 |
| TuHURA Biosciences | 996 | not reported | (8,634)* | 63.7M | 0.1 quarters | 10-QJun 30, 2026 |
| Enanta Pharmaceuticals | 33,419 | 14,359 | (9,972)* | 29.1M | 21.2 quarters | 10-QJun 30, 2026 |
| Alector | 75,472 | 162,866 | (24,154)* | 148.9M | 3.8 quarters | 10-QSep 30, 2026 |
| Galectin Therapeutics | 13,269 | not reported | (2,439)* | 100.8M | 5.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.